Who Paid My Doc
Christopher Walsh
Hematology & Oncology New York, NY Medical Doctor
NPI 1588694095 CMS profile 116995
1190 5Th Avenue, Guggenheim Pav Mt Sinai Hosp Ruttenberg Treatment Ctr, New York, NY 10029
General payments
$303,985
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$575
Through program year 2025, Christopher Walsh of New York, NY is reported in the CMS Open Payments database as having received $303,985 across 222 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $575 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $46,874 | 28 | |
| 2024 | General | $89,624 | 53 | |
| 2023 | General | $41,782 | 35 | |
| 2022 | General | $26,728 | 25 | |
| 2021 | General | $25,199 | 26 | |
| 2020 | General | $22,796 | 9 | |
| 2019 | General | $50,982 | 46 |
Beside peers
- Christopher Walsh
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Christopher Walsh were reported at $46,874. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Christopher Walsh | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $50,982 | $529 | $121–$2,516 | $163 |
| 2020 | $22,796 | $339 | $82–$2,213 | $114 |
| 2021 | $25,199 | $263 | $49–$1,965 | $132 |
| 2022 | $26,728 | $416 | $103–$2,395 | $149 |
| 2023 | $41,782 | $542 | $125–$2,646 | $160 |
| 2024 | $89,624 | $692 | $141–$3,008 | $164 |
| 2025 | $46,874 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 9 billing codesPaid by Medicare
$8,878
Medicare patients
80
Services billed
91
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 49% | |
| Diabetes | 48% | |
| Ischemic heart disease | 46% | |
| Chronic kidney disease | 41% | |
| Heart failure | 34% | |
| Atrial fibrillation | 31% | |
| Depression | 29% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 7 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| ALTUVIIIO |
|
$28,067 | — | — |
| HEMGENIX |
|
$14,979 | — | — |
| HEMLIBRA |
|
$6,999 | — | — |
| REBINYN |
|
$4,463 | — | — |
| HYMPAVZI |
|
$3,000 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 7 in the dashboard with a free accountRecords
222 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in New York
Michael Schuster
Hematology & Oncology · New York, NY
Charles Sawyers
Hematology & Oncology · New York, NY
Manuel Hidalgo-Medina
Hematology & Oncology · New York, NY
Francis Arena
Hematology & Oncology · Lake Success, NY
Sanjeev Jain
Hematology & Oncology · East Patchogue, NY
Ross Levine
Hematology & Oncology · New York, NY
Related records
Hematology & Oncology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.